Collectively, these multifaceted effects highlight that MDM2 inhibition simultaneously alters tumor-intrinsic pathways and the broader immune landscape, reinforcing the rationale for carefully designed combination therapies that exploit p53-mediated immunity while mitigating resistance mechanisms. The gene discussed is TP53; the disease is neoplasm.